TD Private Client Wealth’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

TD Private Client Wealth’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.62K	Sell	54 -7	-11%	-$199	﹤0.01%	1396
2026 Q1	$1.83K	Buy	61 +37	+154%	+$1.23K	﹤0.01%	1303
2025 Q4	$785	Hold	24	–	–	﹤0.01%	1413
2025 Q3	$831	Hold	24	–	–	﹤0.01%	1362
2025 Q2	$672	Buy	+24	New	+$643	﹤0.01%	1327
2020 Q1	–	Sell	-198	Closed	-$41K	–	1101
2019 Q4	$41K	Buy	+198	New	+$36.6K	﹤0.01%	634

Other funds holding LKFT

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

denkapparat Operations Berlin, Germany $306M AUM 40.46% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

CGH

Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

TD Private Client Wealth's LKFT Position: Q2 2026 in Review

TD Private Client Wealth reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 11% in Q2 2026, selling an estimated $199 and leaving 54 shares worth $1.62K. The position accounts for ﹤0.01% of the portfolio, ranked #1396.

TD Private Client Wealth first reported a position in LKFT in Q4 2019 and has held it in 6 quarters since. The position peaked at $41K in Q4 2019. 24 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

TD Private Client Wealth held 54 shares of Lakefront Biotherapeutics American Depositary Shares worth $1.62K as of Q2 2026.
TD Private Client Wealth sold 7 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $199.
Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1396 holding.
TD Private Client Wealth first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2019 and has held it in 6 quarters since.
TD Private Client Wealth's Lakefront Biotherapeutics American Depositary Shares position peaked at $41K in Q4 2019.
24 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.